Recent studies have extensively investigated the use of nanocarriers for targeted drug delivery to cancerous tumors, demonstrating promising outcomes. However, their clinical application reveals significant limitations that necessitate substantial revisions for improved efficacy. Addressing issues such as low cell internalization and limited circulation time can improve their therapeutic efficiency. To enhance circulation time, stealth nanocarriers are preferred, while bioadhesive nanoparticles demonstrate higher cell internalization. In this research, pH-responsive PEGylated polyamidoamine (PAMAM) nanoassemblies were prepared. 2-propionic-3-methylmaleic anhydride (CDM) was used as pH sensitive linkage for the cleavable attachment of poly ethylene glycol (PEG) chains on the surface of PAMAM dendrimers. The obtained PEG-CDM-PAMAM nanoassemblies (PCPNAs) engineered to intelligently address these challenges. The design of PCPNAs enables pH-triggered detachment of PEG chains from the surface at the tumor site, resulting in the exposure of protonated, positively charged residual PAMAM nanoassemblies. Cellular studies revealed enhanced cellular uptake of doxorubicin loaded PCPNAs (DPCPNAs) compared to control PEG-PAMAM nanoassemblies (CPPNAs), pH-insensitive nanoparticles, with similar structures. Therefore, it presents a solution to one of the problems of current nanocarriers characterized by limited cellular internalization. DPCPNAs not only demonstrate enhanced efficacy in reducing tumor volume in 4 T1 tumor-bearing mice but also elevate cancer cell death and growth suppression compared to free doxorubicin. Moreover, toxicological and histopathological evaluations of vital tissues confirmed the biocompatibility of this drug delivery system. The feature of charge switchability resulted in favorable outcomes for DPCPNAs in both in vitro and in vivo experiments.